In one paragraphArticle in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Alessandra VergoriViral Immunodeficiency Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.ORCID 0000-0001-6944-0686 Giulia MatusaliVirology Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.ORCID 0000-0002-2948-4243 Eleonora CiminiLaboratory of Cellular Immunology and Pharmacology, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.ORCID 0000-0002-2659-0868 Alessandro Cozzi LepriInstitute of Global Health, University College London, CREME Center, London KT1 2EE, UK.ORCID 0000-0002-6339-919X Valentina MazzottaViral Immunodeficiency Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.ORCID 0000-0002-0240-7504 Davide MariottiVirology Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.ORCID 0000-0002-7698-1103 Francesca ColavitaVirology Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.ORCID 0000-0003-0640-8667 Simona GiliLaboratory of Cellular Immunology and Pharmacology, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.
Flavia CristofanelliLaboratory of Cellular Immunology and Pharmacology, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.
Marisa FustoViral Immunodeficiency Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.
Roberta GagliardiniViral Immunodeficiency Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.ORCID 0000-0002-6351-2623 Jessica PaulicelliViral Immunodeficiency Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.ORCID 0009-0008-8361-9605 Federico CeciliaViral Immunodeficiency Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.
Enrico GirardiScientific Direction, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.ORCID 0000-0001-8182-5896 Fabrizio MaggiVirology Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.ORCID 0000-0001-7489-5271 Andrea AntinoriViral Immunodeficiency Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.ORCID 0000-0003-2121-4684 Funding
European Commission Horizon 2020 European Virus Archive - GLOBAL, EU project 871029Italian Ministry of Health Ricerca Corrente Linea 2
6 · The paper itselfAbstract
The new Nuvaxovid protein-based and Pfizer-BioNTech mRNA-based vaccines targeting Omicron XBB.1.5 were available during the 2023-2024 autumn/winter vaccination campaign for frail individuals, including people with HIV (PWH). We assessed the immune response in 51 PWH on stable ART who received a booster with either the Nuvaxovid protein-based (
Indexed as
COVID-19COVID-19 VaccinesHIV InfectionsSARS-CoV-2AgedAntibodies, NeutralizingAntibodies, ViralFemaleHumansImmunization, SecondaryInterferon-gammaMaleMiddle AgedAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesInterferon-gammaCOVID-19immunogenicityneutralizing responsePWHSARS-CoV-2 XBB.1.5 vaccine
Identifiers
PMID40332006
PMCPMC12027319
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390